Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The study will select all recruited patients with paroxysmal atrial fibrillation will be
randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before
ablation and last for 3 months. To observe the early relapse of atrial fibrillation and the
changes of white blood cell count, hs-C reactive protein (CRP), interleukin (IL)-6 and tumor
necrosis factor (TNF)-α, and the changes of safety indicators .
This study assumes that the early atrial fibrillation (AF) recurrence will be decreased in
patients with paroxysmal AF if rosuvastatin 20mg/d is received from 7 days before surgery in
these patients who plan to undergo radiofrequency catheter ablation for consecutive 3 months.
Phase:
Phase 4
Details
Lead Sponsor:
The Third Xiangya Hospital of Central South University